Zhongbo Hu

Clinical trials

• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2028
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2030
• A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  Site PI · Recruiting · Phase 3

  Children's Oncology Group

  2025–2031
• A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  Site PI · Recruiting · Phase 2

  Children's Oncology Group

  2024–2033